The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with lewy bodies vs. Normal subjects and patients with Alzheimer's disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kapaki, Elisabeth ^a   Paraskevas, George P ^a   Emmanouilidou, Evangelia ^b   Vekrellis, Kostas ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEWY BODY DISEASE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPINAL PUNCTURE;

EID: 84896730461     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081654     Document Type: Article

References (35)

1. Santacruz KS, Swagerty D (2001) Early Diagnosis of Dementia. Am Fam Physician. 63: 703-714. PubMed: 11237085.
2. Teunissen CE (2002) Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23: 485-508. doi:10.1016/S0197-4580(01)00328-1. PubMed: 12009495.
3. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev Neurol 6: 131-144. doi:10.1038/nrneurol.2010.4.
4. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J et al. (1997) The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 8: 3961-3963. doi: 10.1097/00001756-199712220- 00022. PubMed: 9462474. (Pubitemid 28027217)
5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr et al. (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269. doi:10.1016/j.jalz.2011.05.750. PubMed: 21514250.
6. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L (2011) Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025. doi:10.1016/S1474-4422(11)70213-7. PubMed: 22014436.
7. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G et al. (2000) Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67. doi:10.1016/S0304- 3940(00)01153-8. PubMed: 10841992. (Pubitemid 30332379)
8. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A et al. (2012) α- Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 119: 739-746. doi:10.1007/s00702- 012-0784-0. PubMed: 22426833.
9. Kasuga K, Nishizawa M, Ikeuchi T. (2012) α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis. 437025, pages doi: 10.1155/2012/437025.
10. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325. doi:10.1016/j.expneurol.2008.06.004. PubMed: 18625222.
11. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T et al. (2010) Differential levels of a-synuclein, b-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81: 608-610. doi:10.1136/jnnp.2009.197483. PubMed: 20522869.
12. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C et al. (2011) Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 26: 1428-1435. doi:10.1002/mds.23670. PubMed: 21469206.
13. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C et al. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240. doi:10.1016/S1474-4422(11)70014-X. PubMed: 21317042.
14. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease. Alzheimer Dis Assoc Disord 26: 213-216. doi:10.1097/WAD.0b013e31823899cc. PubMed: 22037599.
15. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L et al. (2013) Low CSF Levels of Both a-Synuclein and the a-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLOS ONE 8 (1): e53250. doi:10.1371/journal. pone.0053250. PubMed: 23308173.
16. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K et al. (2009) CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251: 1-6. doi:10.1016/j.brainres.2008.11.055. PubMed: 19071095.
17. Spies PE, Melis RJ, Sjögren MJ, Rikkert MG, Verbeek MM (2009) Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16: 363-369. PubMed: 19221426.
18. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E et al. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders: a marker of synapse loss? Neurosci Lett 450: 332-335. doi: 10.1016/j.neulet.2008.11.015. PubMed: 19022350.
19. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD et al. (2010) CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 22: 87-95. PubMed: 20847452.
20. Aerts MB, Esselink RAJ, Abdo WF, Bloem BR, Verbeek MM (2012) CSF -synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging. 33:430: e1-e3.
21. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y et al. (2012) Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian. Disorders - Arch Neurol 69: 1445-1452. doi:10.1001/archneurol.2012.1654.
22. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H et al. (2012) Recommendations to standardize pre-analytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 6: 419-430. doi:10.2217/bmm.12.46. PubMed: 22917144.
23. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198. doi:10.1016/0022-3956(75)90026-6. PubMed: 1202204.
24. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E et al. (2009) CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 16: 205-211. doi:10.1111/j.1468-1331.2008.02387.x. PubMed: 19146641.
25. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872. doi:10.1212/01.wnl.0000187889.17253.b1. PubMed: 16237129. (Pubitemid 43970103)
26. Emmanouilidou E, Elenis D, Papasilekas T, Stranjalis G, Gerozissis K, et al. (2011) Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One 6(7):e2222510.1371
27. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER et al. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133: 713-726. doi:10.1093/brain/awq008. PubMed: 20157014.
28. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F et al. (2013) Total CSF a-Synuclein is lower in de novo Parkinson patients than in healthy Subjects. Neurosci Lett 532: 44-48. doi:10.1016/j.neulet.2012.11.004. PubMed: 23149132.
29. Barbour R, Kling K, Anderson JP, Banducci K, Cole T et al. (2008) Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. Neurodegener Dis 5: 55-59. doi:10.1159/000112832. PubMed: 18182779.
30. van Geel WJ, Abdo WF, Melis R, Williams S, Bloem BR et al. (2008) A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J Neurosci Methods 168: 182-185. doi:10.1016/j.jneumeth. 2007.09.021. PubMed: 17976734.
31. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute of Aging Working Group (1998) Concensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's disease". Neurobiol Aging 19: 109-116. doi:10.1016/S0197- 4580(98)00022-0. PubMed: 9558143.
32. Tiraboschi P, Guerra UP (2010) How to Distinguish Dementia with Lewy Bodies from Alzheimer Disease? Open Nuclear Medicine Journal 2: 58-62. doi:10.2174/1876388X01002020058.
33. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J et al. (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT-SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6: 305-313. doi:10.1016/S1474-4422(07)70057-1. PubMed: 17362834. (Pubitemid 46367938)
34. Rinne JO, Sahlberg N, Ruottinen H, Någren K, Lehikoinen P (1998) Striatal uptake of the dopamine reuptake ligand [11C] beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50: 152-156. doi:10.1212/WNL.50.1.152. PubMed: 9443472.
35. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL et al. (1995) Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 37: 300-312. doi:10.1002/ana.410370306. PubMed: 7695230.